Jiangsu Hengrui Pharma stock spikes 10% to 4-year high on drug development deal with GSK – here's what the company does
The programs were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I), and Oncology pipeline, having been assessed for their potential best-in-class or first-in-class profiles.
The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong, Macau, and Taiwan) for a potential best-in-class PDE3/4 inhibitor (HRS-9821), which is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, regardless of background therapy, GSK said in its filing on Monday.
The British pharmaceutical giant added that HRS-9821 supports its ambition to treat patients across the widest spectrum of COPD, including those who experience continued dyspnea (shortness of breath) or are unlikely to receive inhaled corticosteroids or biologics, based on their disease profile.
The agreements also feature a pioneering, large-scale collaboration to develop up to 11 additional programs besides HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programs up to the completion of Phase I trials, including trials involving patients outside of China.
GSK will have the exclusive option to further develop and commercialize each program worldwide (excluding mainland China, Hong Kong, Macau, and Taiwan) at the end of Phase I or earlier, at its discretion, and will also have program substitution rights.
GSK has agreed to pay $500 million in upfront fees across the agreements, including for the license of the PDE3/4 program. The potential total value of future success-based development, regulatory, and commercial milestone payments to Hengrui Pharma could reach approximately $12 billion if all programs are optioned and all milestones are met.
Additionally, Hengrui Pharma will be eligible for tiered royalties on global product net sales (excluding mainland China, Hong Kong, Macau, and Taiwan). The license to HRS-9821 remains subject to customary conditions, including regulatory clearance under the Hart-Scott-Rodino Act in the United States.
Tony Wood, Chief Scientific Officer at GSK, said, 'We're delighted to announce these exciting agreements with Hengrui Pharma, which complement our already extensive pipeline. This deal reflects our strategic investment in programs that address validated targets, increasing the likelihood of success, while giving us the option to advance the assets with the greatest potential for patient impact.'
Founded in 1970, Hengrui Pharma is a global pharmaceutical company dedicated to research, development, and commercialization of high-quality medicines to address unmet clinical needs.
With a global R&D network of 14 centers and over 5,500 professionals, Hengrui's therapeutic focus includes oncology, metabolic and cardiovascular diseases, immunological and respiratory disorders, and neuroscience.
To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China.
Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
25 minutes ago
- Mint
Banks lead Australian shares to record close as inflation data lifts rate-cut hopes
Softer inflation data boosts rate-sensitive stocks Banks rise to more than one-week high ASX 200 eyes fourth consecutive month of gains July 30 (Reuters) - Australian shares rallied to a record close on Wednesday, led by heavyweight banks as softer inflation data boosted hopes for an interest rate cut next month, while improved prospects of an extension to the Sino-U.S. trade truce added to the relief. The S&P/ASX 200 benchmark index closed 0.6% higher at 8,756.40 points. The benchmark is on track to close July nearly 2% higher, its fourth straight month of gains. Australian consumer prices grew at the slowest pace in over four years in the June quarter, adding to the mounting pressure on the Reserve Bank of Australia to reduce borrowing costs at its policy meeting next month. "It (inflation data) also lowers the bar for faster and deeper easing ahead of year-end as disinflation broadens across both goods and services," Hebe Chen, market analyst at Vantage Markets said. Banks, among the biggest beneficiaries of lower interest rates, led the financial index 1.1% higher to a more than one-week high. All the "Big Four" banks advanced between 0.7% and 1.6%. Rate-sensitive real estate stocks climbed 1.3%. Mirvac Group added 2.7%, while Dexus rose 1.4%. Meanwhile, U.S. and Chinese officials agreed to seek an extension of their 90-day tariff truce, defusing an escalating trade war between the world's two biggest economies that threatens global growth. For Australia, the news offers a welcome reprieve -stabilising export demand for iron ore and LNG and providing near-term support for resource-heavy firms amid ongoing external uncertainty, said Chen. Miners ended marginally lower with BHP down 0.5% and Rio Tinto ending 1% lower. The world's biggest iron ore miner is expected to announce its interim results after market close. Energy stocks ticked 0.1% down, while gold stocks rose 0.3%. New Zealand's benchmark S&P/NZX 50 index fell 0.6% to 12,855.97 points. (Reporting by Sneha Kumar in Bengaluru; Editing by Harikrishnan Nair)
Mint
25 minutes ago
- Mint
Motilal Oswal calls current market phase the 'middle overs' — Time for strategy, not aggression
India's market journey has moved into a consolidation phase resembling the 'middle overs' in a cricket match, according to the July 2025 Alpha Strategist report by Motilal Oswal Private Wealth (MOPW). Drawing a cricketing analogy, the firm likens the current investment environment to a high-scoring pitch with stable macro fundamentals, and suggests investors focus on strategy and discipline rather than aggressive plays during this phase. MOPW says the earlier Mar–Apr 2025 correction served as the 'PowerPlay overs,' where entry points offered attractive value, resulting in quick gains over the following three months. However, post-rebound, the markets have entered the "middle overs" — a period where investors should aim to rotate strike rather than go for sixes. This means accumulating quality assets, managing risk carefully, and positioning portfolios for long-term performance rather than chasing short-term momentum. The report underlines that this phase in markets calls for patience and careful navigation, just as middle overs in cricket require intelligent shot selection and steady run accumulation. Blind aggression, it warns, could be counterproductive at this stage. MOPW highlights that global equity markets have witnessed divergent trends in 2025, with geopolitical uncertainty dominating the first half of recent months. However, in the latter half, a relative sense of calm returned despite tensions between Iran and Israel and the temporary disruption of oil flows through the Strait of Hormuz. Notably, crude oil prices, after spiking briefly, resumed a downward trend — a sign of the global economy's reduced dependence on the Middle East. In the US, concerns are rising over a widening twin deficit. The 'Big Beautiful Bill' is expected to push the fiscal gap wider by USD 3.3 trillion over the next decade, with the current account deficit projected to exceed 6 percent — levels last seen in 2006. While trade agreements with partners like India and the EU are underway, MOPW notes that delays in negotiations may extend uncertainty into the next quarter. On the domestic front, MOPW remains constructive on India's outlook, with positives such as robust services exports, Production Linked Incentive (PLI) payoffs, and Free Trade Agreements (FTAs) offsetting global headwinds. Benign crude prices are also acting as a macro stabiliser. The country's GDP is expected to grow between 6.2–6.7 percent, driven by government spending and resilient consumption. However, near-term high-frequency data presents a mixed bag. GST collections grew in single digits in June, while IIP slowed to 1.2 percent in May from 2.7 percent in April. In contrast, manufacturing and services PMIs hit multi-month highs, showing sectoral resilience. Foreign Institutional Investor (FII) flows have remained modestly positive over the past three months, but equity mutual fund flows have decelerated. Historical data suggests that in nearly 90 percent of instances, negative FII flows have coincided with negative monthly equity returns, even if Domestic Institutional Investors (DIIs) continued to buy. Meanwhile, valuations across sectors and market caps have risen sharply, calling for more selective allocation. Equities: The equity allocation strategy remains neutral with a suggested mix of 65 percent in large caps and 35 percent in mid- and small-cap stocks. For under-allocated investors, the firm recommends considering lump-sum allocations to hybrid funds. In the case of pure equity categories, staggered investments via SIPs or STPs are advised to manage market volatility effectively. Fixed Income: With the Reserve Bank of India proactively easing policy and ensuring adequate liquidity, the yield curve has steepened. MOPW suggests an overweight position on accrual strategies across credit categories, including Private Credit Strategies, InvITs, and select NCDs. Arbitrage funds, income-plus-arbitrage Fund of Funds, and conservative equity savings strategies may also be considered as tax-efficient fixed income alternatives. However, with limited room for further capital appreciation in long-duration bonds, the report advises gradually reducing exposure to 10–15 year duration strategies. Gold & Silver: The stance on gold remains neutral, while silver is seen as a tactical bet rather than a substitute for gold. The report cautions investors not to treat silver as a safe-haven hedge in the same way as gold. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Hindustan Times
an hour ago
- Hindustan Times
Down on sales, coffee giant Starbucks gets makeover: Protein focus, new dark roast, and more
After six quarters of slipping sales, Starbucks is brewing one of its boldest transformations so far, including high-protein cold foam drinks, faster service, and a fresh hospitality model in the US. One of Starbucks' major bets is on a new customer service model called the "Green Apron Service.(Bloomberg) One of the coffee giant's major bets is on a new customer service model called the 'Green Apron Service'. Tested at 1,500 stores over eight weeks, it focuses on better staffing during peak hours, hospitality training, and a renewed emphasis on speed and personalisation. Also Read | Starbucks makes its 'secret menu' official with new $25K drink contest; Here's what's on it Chairman and CEO Brian Niccol said Starbucks is planning to roll it out across the US starting in mid-August, expressing optimism even as the numbers show a bumpy road ahead. 'I think we'll become famous for Green Apron Service and be the defining customer service company that I think Starbucks should be,' Niccol said. How is Starbucks changing in the US? New software is also helping stores sequence orders, cutting down on wait times, AP reported. Niccol said 80% of in-store orders are now made in four minutes or less, a target he set last fall. In addition to protein drinks, Starbucks plans to introduce new baked goods and a new dark roast coffee next year. It will also test beverages made with coconut water, customizable energy drinks, and gluten-free and high-protein foods. Also Read | What is Luckin Coffee? Chinese Starbucks competitor opens first stores in THIS US state, offers affordable beverages Niccol also said Starbucks has been working closely with employees to develop new food and drink items that can be prepared quickly and consistently. The CEO also said that Starbucks was closing or modifying some of its approximately 90 mobile order-only storefronts, and it is developing a store prototype with 32 seats and a drive-thru window that costs 30% less than the company's current store design. What's driving this change? In its fiscal third quarter, Starbucks reported revenue of $9.5 billion — slightly above analyst expectations, but same-store sales in the US dropped by 2%, and overall transactions were down 4%. That was a bigger decline than Wall Street expected, and it was the sixth straight quarter that the Seattle-based company reported lower same-store sales. Also Read | This Starbucks job pays ₹3 crore a year but your office will be 35,000 feet in the air Similar stores were set up in China as well, but even as its sales picked up in China, Starbucks' same-store sales in the US fell 2% in the April-June period. US customers spent more per order, but transactions fell 4%, the company reported. The company said its net income fell 47% to $558 million in the April-June period. Adjusted for one-time items, its earnings fell 46% to 50 cents per share for the quarter, lower than the 65 cents analysts had forecast. (with AP inputs)
